SITE002-0209

SITE002 (USA) › SITE002-0209

SITE002-0209

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2026-05-05

enrolled

AEs

1

Serious

0

Dropout signal

–

Adverse events

1

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-11 (study day 121); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.